Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
This article was originally published in The Pink Sheet Daily
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.
You may also be interested in...
The rheumatoid arthritis agent is expected to be available by the end of February.
First quarter earnings preview: US drug pricing reform, an uncertain regulatory outlook and new focus on M&A are rising challenges that could put the industry's growth at risk.
Janssen's net drug prices declined for the fourth year in a row in 2020, while list prices increased 3.8%, according to the company's drug pricing report.